个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zheng Baomin[1] ; He Meilin[2] ; Han Yaqian[3] ; Jiang Xin[4] ; Ou Xiaomin[5] ; Zhang Peng[6] ; Guo Ruyuan[7] ; Li Jingao[8] ; Zhang Ximei[9] ; Qiao Qiao[10] ; Wu Hui[11] ; Hu Man[12] ; Feng Mei[13] ; Tu Wenyong[14] ; Yi Junlin[2,15,*1] ;
机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, China [2]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [3]Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China [4]Department of Radiation Oncology,The First Hospital of Jilin University, Changchun, China [5]Department of radiation oncology, Fudan University Shanghai Cancer Center, China [6]Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan, China [7]Deparment of Head and Neck Radiotherapy, Shanxi Tumor Hospital, China [8]Department of Radiation Oncology, Jiangxi Cancer Hospital, China [9]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, China [10]Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China [11]Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou, China [12]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China [13]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, China [14]Department of Oral and Maxillofacial Head and Neck Oncology Shanghai Ninth People's Hospital, China [15]National Cancer Center/National Clinical Research Center for Cancer, Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, China
出处：
DOI： 10.2174/0115680096281982240117114819
ISSN：

关键词： Nimotuzumab radiotherapy chemoradiotherapy head and neck cancer nasopharynx

摘要：
The present meta-analysis aimed to evaluate the efficacy and safety of adding nimotuzumab to radiotherapy (RT) or chemoradiotherapy (CRT).Prospective randomized controlled studies at EMBASE, PubMed, and the Cochrane Library from January 1, 2010, to October 1, 2022, were searched. Data on the overall survival (OS), progress-free survival (PFS), disease-free survival (DFS), complete response rate (CRR), objective response rate (ORR), and all grade adverse events were collected from the enrolled publications. OS was the primary measurement indicator. Pooled analysis was performed with relative risks (RRs), hazard risks (HRs), and their corresponding 95% confidence intervals (CIs) in the software Stata SE 16.0.Six randomized controlled studies were included in the analysis of the overall pooled effect. As compared to the control group, the nimotuzumab intervention group exhibited improved OS by 21% (pooled HR=0.79,95% CI: 0.64-0.98, P=0.028), along with PFS up to 31% (HR=0.69, 95% CI: 0.55-0.86, P=0.001) and DFS up to 29% (HR=0.71, 95% CI: 0.56-0.91, P=0.006), increased CRR as 50% (RR=1.50, 95%CI:1.09-2.04; P=0.012), and ORR as 35% (RR=1.35, 95%- CI:1.04-1.73; P=0.022). Regarding safety, nimotuzumab in combination with RT or CRT did not increase the incidence of all grade adverse events (pooled-RD=-1.27, 95%CI:-2.78-0.23, P=0.099).The present meta-analysis has demonstrated that nimotuzumab, in combination with RT or CRT, could provide survival benefits and increase response rates. Its safety profile has been found to be controllable.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q3 ONCOLOGY
最新[2023]版：
Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, China
通讯作者：
通讯机构： [2]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [15]National Cancer Center/National Clinical Research Center for Cancer, Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, China [*1]National Cancer Center/National Clinical Research Center for Cancer, Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, China
推荐引用方式(GB/T 7714)：
Zheng Baomin,He Meilin,Han Yaqian,et al.Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis[J].CURRENT CANCER DRUG TARGETS.2024,24(9):952-966.doi:10.2174/0115680096281982240117114819.
APA：
Zheng Baomin,He Meilin,Han Yaqian,Jiang Xin,Ou Xiaomin...&Yi Junlin.(2024).Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.CURRENT CANCER DRUG TARGETS,24,(9)
MLA：
Zheng Baomin,et al."Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis".CURRENT CANCER DRUG TARGETS 24..9(2024):952-966

相关文献

[1]Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer [2]MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer [3]Advancements of radiotherapy for recurrent head and neck cancer in modern era [4]Spatially fractionated radiotherapy (Lattice SFRT) in the palliative treatment of locally advanced bulky unresectable head and neck cancer [5]Patient-Family Caregiver Concordance in Assessment of Psychological Distress of Chinese Patients with Head and Neck Cancer during Chemoradiotherapy [6]Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review [7]Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer [8]Early nutrition support therapy to improve the nutrition status of head and neck cancer patients accepted concurrent chemoradiotherapy (NSTIP): Interim analysis from a prospective randomized controlled clinical study [9]Body mass index and the risk of head and neck cancer in the Chinese population. [10]LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号